Key facts
- Novo Nordisk CEO Mike Doustdar believes the obesity drug market will not be dominated by a single player.
- He anticipates market segmentation as new obesity treatments, including pills, become available.
- Doustdar compared the market to the diverse insulin offerings for diabetes, with multiple brands serving different needs.
- Novo's pill version of Wegovy currently holds a 90% market share in the oral GLP-1 segment.
- The company's experimental drug CagriSema is still considered a potentially powerful addition to the treatment landscape.
Novo Nordisk CEO Mike Doustdar stated that investors are underestimating the demand for differentiation within the obesity drug market, suggesting it will not become a winner-take-all competition with rival Eli Lilly. Doustdar believes that as new treatment options, including pills, emerge, the market will segment, allowing various drugs to cater to different patient needs. He drew a parallel to Novo Nordisk's successful insulin business for diabetes, which offers 12 different brands rather than relying on a single dominant product.
Currently, Novo's Wegovy injection is a leading GLP-1 weight-loss drug, but Eli Lilly's Zepbound is also a significant competitor in a market projected to exceed $100 billion annually by 2030. Doustdar emphasized that patients are beginning to understand which GLP-1 drug is best suited for them, anticipating further segmentation with future drug approvals. He described the market not as a 'Coke versus Pepsi' scenario but as a broader selection akin to 'Coke and Pepsi and Fanta and Dr Pepper and Red Bull.'
Novo's pill version of Wegovy currently holds a 90% market share in the oral GLP-1 segment, supported by data showing superior weight loss compared to Lilly's Foundayo pill. Doustdar indicated that a 50-50 market split between oral medications and injections would be a favorable outcome for Novo. Despite some investor disappointment with its experimental next-generation obesity drug CagriSema, which showed an average weight loss of 23% compared to Zepbound's over 25%, Doustdar asserted it would still be a valuable addition to doctors' treatment options.